Chronic kidney disease: when the filters fail

CPD
By
AP Staff
-

References

  1. Kidney Health Australia. Chronic kidney disease (CKD) management in primary care. 5th ed. Melbourne: Kidney Health Australia; 2024. At: www.assets.kidney.org.au/resources/KHA-CKD-Handbook-5th-Ed-July2024.pdf
  2. Australian Institute of Health and Welfare. Chronic kidney disease: Australian facts. Canberra: AIHW; 2024. At: www.aihw.gov.au/reports/chronic-kidney-disease/chronic-kidney-disease/contents/summary
  3. Tesfaye W, Krass I, Sud K, et al. Impact of a pharmacy-led screening and intervention in people at risk of or living with chronic kidney disease in a primary care setting: a cluster randomised trial protocol. BMJ Open 2023;13(12):e079110. At: bmjopen.bmj.com/content/13/12/e079110
  4. Lim WH, Johnson DW, Hawley C, et al. Type 2 diabetes in patients with end-stage kidney disease: influence on cardiovascular disease-related mortality risk. Med J Aust 2018;209(10):440–6. At: pubmed.ncbi.nlm.nih.gov/30332936/
  5. Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet 2017;389(10075):1238–52. At: thelancet.com/journals/lancet/article/piiS0140-6736(16)32064-5/fulltext
  6. Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008;73:19–33.
  7. Briganti EM, Branley P, Chadban SJ, et al. Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab kidney study. Am J Kidney Dis 2002;40:704–12.
  8. Magagnoli L, Cozzolino M, Evans M, et al. Association between chronic kidney disease-mineral and bone disorder biomarkers and symptom burden in older patients with advanced chronic kidney disease: results from the EQUAL study. Clin J Am Soc Nephrol 2024;19(10):1240–52. At: https://pubmed.ncbi.nlm.nih.gov/39037951/
  9. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339(20):1448–56. At: www.nejm.org/doi/full/10.1056/NEJM199811123392007
  10. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105(4S):S117–314.
  11. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2025 clinical practice guideline for anaemia in chronic kidney disease (public review draft). 2024. At: https://kdigo.org/wp-content/uploads/2024/11/KDIGO-2025-Anemia-in-CKD-Guideline_Public-Review-Draft_Nov42024.pdf
  12. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017;7:1–59. At: https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf
  13. Laub MR, Conway PT, Trzebinska D, et al. The pharmacist’s role in transforming nephrology care. Am J Health Syst Pharm 2025;82(12):672–80. At: academic.oup.com/ajhp/advance-article/doi/10.1093/ajhp/zxaf048/8092354
  14. Castelino RL, Tesfaye W. Chronic kidney disease and quality use of medicines. Aust Pharm 2024;43:36–44.
  15. Roberts J. Ozempic cleared for kidney disease treatment. NewsGP 2025 Aug 20. At: www1.racgp.org.au/newsgp/clinical/ozempic-cleared-for-kidney-disease-treatment